Eli Lilly strikes AI drug discovery deal with US biotech

The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

As AI shakes up pharma and biotech, can patent law keep up?

22 May 2025 Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.

Americas

LSPN: Counsel grapple with AI’s impact on training and critical thinking

8 May 2025 Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025.

Americas

Strategic IP protection for biotech-related GenAI

24 April 2025 Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.

More features

Why AI drug discovery has an IP problem and what can be done

Blank Rome adds more patent attorneys in ‘strategic expansion’

Simmons & Simmons patent litigator jumps ship

ITC probes on the rise, but gender parity lags behind

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Eli Lilly strikes AI drug discovery deal with US biotech

More on this story

Editor's picks

Editor's picks

More features